The nociceptin/orphanin FQ (N/OFQ)-Nociceptin Opioid Peptide (NOP) receptor system, is a relatively new discovery in the context of the human opioid system. The NOP receptor although like the classical Mu Opioid Receptor (MOP), in its intracellular signaling pathways, exhibits starkly distinct effects on pain modulation. Preclinical rodent studies with NOP receptor agonists revealed significant findings on the effect of N/OFQ in pain modulation. The effects were influenced by a variety of factors such as dosage, site of administration, and pain modality. Conversely, studies performed on primates indicated consistent potent analgesic effects, notably lacking typical opioid side effects like respiratory depression and dependence. Furthermore, bifunctional NOP/MOP agonists have shown potential as viable alternatives to traditional opioids due to their improved safety profiles. These dual-action compounds demonstrate strong analgesic effects while mitigating dose-limiting adverse reactions typically associated with MOP receptor activation. This review highlights the physiological role of the nociceptin system and provides a comprehensive overview of recent advancements in the development of selective NOP agonists and bifunctional NOP/MOP agonists, such as AT-121, BU08028, BU10038, Cebranopadol, which have demonstrated promise in preclinical studies. We also discuss future trends in nociceptin agonist research, emphasizing their potential to serve as novel, effective analgesics with a superior safety profile compared to traditional opioids.